US stocks drop as FDA rejects lung cancer drug approval

TL;DR: US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%. Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab. US Food and Drug Administration declined to approve Summit Therapeutics' experimental lung cancer drug ivonescimab. Summit Therapeutics shares fell 14% at $12.16 in morning trading after FDA decision.

ReutersNov 16, 2026

From · · · 1m

TL;DR: US stocks drop as FDA rejects lung cancer drug approval

Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab.

US FDA declined to approve Summit Therapeutics' lung cancer drug ivonescimab, causing shares to drop 14%. Summit Therapeutics shares fall 14% after US FDA rejects lung cancer drug ivonescimab. US Food and Drug Administration declined to approve Summit Therapeutics' experimental lung cancer drug ivonescimab. Summit Therapeutics shares fell 14% at $12.16 in morning trading after FDA decision.

  • FDA rejects lung cancer drug
  • Shares drop 14%
  • Drug study results
  • Regional patient outcomes

Read the story version — the same reporting as a swipeable deck of 7 cards.

Read the original on The Economic Times

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on us stocks and related topics.